Centiva Capital’s Roivant Sciences ROIV Stock Holding History

Centiva Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,000	Closed	-$693K	–	2167
2026 Q1	$693K	Sell	25,000 -195,000	-89%	-$5.01M	0.01%	708
2025 Q4	$4.77M	Hold	220,000	–	–	0.04%	264
2025 Q3	$3.33M	Buy	220,000 +200,000	+1,000%	+$2.48M	0.03%	294
2025 Q2	$225K	Buy	+20,000	New	+$217K	﹤0.01%	1292

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Centiva Capital's ROIV Position: Q2 2026 in Review

Centiva Capital sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 7,596 shares — an estimated $210K sold.

Centiva Capital first reported a position in ROIV in Q1 2022 and held it in 8 quarters. The position peaked at $2.06M in Q2 2022. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Centiva Capital reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Centiva Capital sold 7,596 Roivant Sciences shares in Q2 2026, an estimated $210K.
Centiva Capital first reported a position in Roivant Sciences in Q1 2022 and held it in 8 quarters.
Centiva Capital's Roivant Sciences position peaked at $2.06M in Q2 2022.
500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.